查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990215

可待因市场：依产品类型、剂型、应用、通路和最终用户划分－2026-2032年全球市场预测

Codeine Market by Product Type, Form, Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，可待因市场价值将达到 43.1 亿美元，到 2026 年将成长至 45 亿美元，到 2032 年将达到 59.8 亿美元，复合年增长率为 4.79%。

主要市场统计数据
基准年 2025 43.1亿美元
预计年份：2026年 45亿美元
预测年份：2032年 59.8亿美元
复合年增长率 (%) 4.79%

可待因作为医疗保健领域治疗手段的全面概述，包括其概述、临床作用、监管复杂性、安全问题以及不断变化的相关人员期望。

可待因在现代临床实践中占据复杂而重要的地位，它长期以来一直被用作镇痛药和止咳药，同时也是监管和公共卫生措施的重点关注对象。临床上，可待因的药理特性及其在复方製剂中的应用使其在多种疼痛管理和止咳适应症中保持着广泛的作用。然而，其代谢特性以及患者反应的潜在差异性要求在复方製剂中对其进行谨慎管理。近年来，卫生部门和医生更加重视风险降低、患者选择以及适合不同年龄层的製剂选择，尤其是在儿童和老年人群中。

本文详细回顾了受更严格的监管、替代疗法、供应稳定性和製剂趋势驱动的可待因市场格局的关键变化。

可待因领域正经历许多变革，这些变革正在重塑临床实践、供应链结构和监管参与方式。多个司法管辖区加强监管，提高了製剂、标籤和上市后监测的标准，促使生产商和临床医生优先考虑风险管理措施和循证合理用药方案。同时，针对特定适应症的替代疗法和非阿片类药物的推广，正在改变製剂趋势，更加註重多方面的疼痛管理方法以及在临床适用情况下使用非阿片类镇咳药。

评估 2025 年美国关税措施对可待因供应链、原料药采购成本、临床应用和生产的累积影响。

美国2025年实施的关税措施对全球可待因生态系统产生了累积性影响，促使筹资策略发生累积，活性成分（API）采购成本差异显现，并促使企业重新评估库存和製造地。影响关键中间体和成品进口的关税变化，促使製造商考虑近岸外包和供应商多元化，以确保供应的连续性，同时也提升了垂直整合生产能力的战略价值。为此，采购团队正在扩展供应商合格流程，并加强供应商绩效监控，以保护临床用药免受暂时性贸易摩擦的影响。

透过细分洞察，揭示产品类型、配方选择、临床应用、分销管道和最终用户环境等方面的需求模式。

细分市场分析揭示了不同的需求因素和临床要求如何转化为差异化的产品开发和分销策略。依产品类型划分，硫酸可待因、磷酸可待因、硫酸可待因和复方製剂之间的差异决定了化学原料的采购管道、製剂的适用性以及监管文件的结构。复方製剂通常需要额外的动态和安全性验证。按剂型划分，注射剂、糖浆和片剂之间的动态影响着临床应用案例和供应链的选择。注射剂的需求受肌肉注射和静脉注射两个细分市场的影响，这两个细分市场对无菌性和低温运输的要求各不相同。糖浆的选择受含糖和无糖选项的影响，这与患者的人口统计特征和标籤要求有关。另一方面，片剂必须在缓释和速效之间取得平衡，以满足镇痛方案的要求。

区域比较分析揭示了监管差异、获取临床服务的挑战、供应链脆弱性以及推动策略重点的需求趋势。

区域趋势对可待因製剂的监管、供应和临床应用有深远影响，区域差异既影响短期因应措施，也影响长期策略。在美洲，法律规范和医疗服务体系导致集中采购与製剂多样化并存的局面，因此供应商的可靠性和分销责任至关重要。在欧洲、中东和非洲，管理体制分散、报销环境各异，加上对药物安全监测的高期望，因此需要製定兼顾区域差异的监管策略，并进行严格的上市后监测。在亚太地区，医疗基础设施的快速扩张和区域间生产能力的差异为本土生产创造了机会，同时也需要统一品质标准，以实现跨境供应。

公司对创新策略、产品组合多元化、生产适应性和伙伴关係的洞察，塑造了竞争激烈的可待因市场。

可待因市场的企业层面趋势反映了创新、营运柔软性和遵守日益严格的监管要求之间的平衡。主要企业和学名药生产商优先考虑产品组合多元化和製剂创新，以在解决安全问题和满足患者偏好的同时，保持其临床意义。对无糖糖浆製剂、儿童剂型和缓释片的策略性投资表明，产品设计如何能够降低特定临床风险，并提高某些患者群体的用药依从性。

业界领导者运用这些极具影响力和可操作性的建议，在平衡患者用药、监管合规、供应稳定和负责任的鸦片类药物管理方面发挥重要作用。

为了在应对日益增长的安全期望和供应不确定性的同时，保障患者获得治疗，行业领导者应采取一系列切实有效的措施。加强供应商网路并确保原料药的替代来源，将降低单一来源风险，并为应对贸易政策或物流问题时灵活调整生产策略创造空间。同时，投资研发多样化的製剂，例如无糖糖浆、儿童用药和缓释片，将使产品线能够与不断变化的临床指南和患者需求保持一致。这些投资，加上强化药物监测系统以及与监管机构的积极合作，必须确保附加檔和使用说明反映最新的实证医学证据。

透过结合与主要相关人员的访谈、监管审查、临床证据的整合和多方面的检验，调查方法提供了可操作的见解。

本分析的研究基础是将与关键相关人员的对话、监管审查、临床证据整合以及严谨的多方面检验相结合，从而得出可操作的见解。关键资讯来源包括与临床医生、监管专家、供应链经理和销售代表的结构化访谈，这些访谈捕捉了实际营运和新兴的临床模式。研究人员系统性地审查了监管文件、临床指南和同行评审文献，并根据当前的护理标准和安全预期进行解释。整合这些资讯使得研究人员能够交叉检验临床趋势、药物偏好和分销趋势。

结论：整合临床、监管、供应链和商业性要求，以决定目前的治疗用途和适当的用途优先事项。

总之，可待因製剂的治疗和商业性前景受多种因素的复杂影响，包括监管力度加大、临床替代方案不断涌现、供应链持续存在漏洞，以及需要谨慎管理以最大限度减少不良反应。应对这些因素需要製定一项综合策略，将产品设计、供应链和与临床医生的合作相结合，从而在确保安全用药的同时，降低滥用风险。法律规范的不断演变和贸易趋势对采购和定价的影响，积极调整其生产、采购和临床支持模式的相关人员将更有利于维持稳定的供应和临床意义。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 可待因市场：依产品类型划分

  • 硫酸可待因
  • 磷酸可待因
  • 硫酸可待因
  • 组合配方

第九章：可待因市场：以剂型划分

  • 注射药物
    • 肌肉内部
    • 静脉
  • 糖浆
    • 糖
    • 无醣
  • 药片
    • 缓释
    • 立即生效

第十章：可待因市场：依应用领域划分

  • 止咳药
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛

第十一章 可待因市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 可待因市场：依最终用户划分

  • 诊所
  • 居家照护
  • 医院

第十三章 可待因市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 可待因市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 可待因市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国可待因市场

第十七章：中国的可待因市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Accord Healthcare by Intas Pharmaceuticals
  • Advik Pharma
  • AstraEureka Pharmaceuticals
  • Bristol Laboratories Limited
  • Crescent Pharma Limited
  • Johnson Matthey Plc
  • Noramco, Inc.
  • Omnica Laboratories
  • Pfizer Inc.
  • Professional Compounding Centers of America, Inc.
  • SANOFI WINTHROP INDUSTRIE
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-99555D550530

The Codeine Market was valued at USD 4.31 billion in 2025 and is projected to grow to USD 4.50 billion in 2026, with a CAGR of 4.79%, reaching USD 5.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.31 billion
Estimated Year [2026] USD 4.50 billion
Forecast Year [2032] USD 5.98 billion
CAGR (%) 4.79%

Comprehensive overview of codeine therapeutics, clinical roles, regulatory complexities, safety concerns, and evolving stakeholder expectations in healthcare

Codeine occupies a complex and consequential position within contemporary therapeutic practice, serving as both a long-established analgesic and antitussive agent and a focal point for regulatory scrutiny and public health policy. Clinically, codeine's pharmacologic profile and its inclusion in combination products have sustained its role across a range of pain management and cough suppression indications, while its metabolism and potential for variable patient response have driven careful stewardship in prescribing. Over recent years, health authorities and prescribers have intensified emphasis on risk mitigation, patient selection, and age-appropriate formulations, particularly where pediatric and elderly populations are concerned.

As a result, manufacturers, clinicians, and distributors operate in an environment where supply continuity, formulation innovation, and compliance with divergent national regulations converge. This environment demands a layered understanding of product variants, permissible formulations, and the interplay between clinical utility and safety obligations. Transitional technologies such as tele-prescribing, combined with evolving pharmacovigilance expectations, are changing how codeine products are accessed and monitored. Consequently, stakeholders must balance therapeutic access with robust mitigation of misuse and diversion risks while maintaining operational resilience across manufacturing and distribution channels.

In-depth review of major shifts reshaping the codeine landscape driven by regulatory tightening, therapeutic substitution, supply resilience and prescribing

The landscape for codeine is undergoing several transformative shifts that are redefining clinical practice, supply chain architecture, and regulatory engagement. Regulatory tightening in multiple jurisdictions has elevated the standards for prescribing, labeling, and post-market surveillance, prompting manufacturers and clinicians to prioritize risk management measures and evidence-based stewardship programs. Concurrently, therapeutic substitution and the expansion of non-opioid alternatives for specific indications have altered prescribing trajectories, encouraging greater emphasis on multimodal pain management pathways and non-opioid antitussives where clinically appropriate.

Supply chain resilience has become a strategic imperative as raw material controls, geopolitical tensions, and logistic bottlenecks expose vulnerabilities in active pharmaceutical ingredient sourcing and finished product distribution. At the same time, innovation in formulations-ranging from sugar-free syrups to extended-release tablets and combination products-reflects both patient-centric demands and regulatory accommodation for safer dosing. Digital tools for prescribing, adverse-event monitoring, and adherence support are gaining traction, aligning clinical decision-making with real-world safety data. Together, these shifts are creating a healthcare ecosystem in which manufacturers, payers, and providers must coordinate to ensure therapeutic access while meeting heightened expectations for safety, transparency, and supply continuity.

Evaluation of cumulative effects from United States tariff actions in 2025 on codeine supply chains, API sourcing costs, clinical access, and manufacturing

United States tariff actions implemented in 2025 have exerted a cumulative effect on the global codeine ecosystem by redirecting sourcing strategies, exposing cost differentials in active pharmaceutical ingredient procurement, and prompting reassessments of inventory and manufacturing footprints. Tariff changes affecting key intermediates and finished product imports have encouraged manufacturers to evaluate nearshoring and supplier diversification as mechanisms to protect supply continuity, while also increasing the strategic value of vertically integrated production capabilities. In response, procurement teams have expanded supplier qualification processes and intensified supplier performance monitoring to insulate clinical supply from episodic trade friction.

Clinicians and health systems have experienced indirect consequences through procurement cycles and formulary reviews, leading to an increased preference for products with stable supply chains and transparent provenance. Pharmaceutical manufacturers have accelerated conversations on domestic production capacity, contract manufacturing partnerships, and API substitution where scientific and regulatory frameworks permit. Regulatory authorities and trade policymakers have, in some cases, instituted exemptions or expedited review pathways for essential medicines to preserve clinical access, and private-sector actors have adopted hedging strategies in inventory management to mitigate near-term disruptions. The net effect is a recalibration of operational priorities where trade policy, clinical continuity, and production agility intersect.

Segmentation insights revealing demand patterns across product types, formulation options, clinical applications, distribution channels and end-user settings

Segmentation analysis reveals how heterogeneous demand drivers and clinical requirements translate into differentiated product development and distribution strategies. Based on product type, distinctions among Codeine Hydrochloride, Codeine Phosphate, Codeine Sulfate, and Combination Products determine chemical sourcing pathways, formulation compatibility, and regulatory dossier composition, with combination products often requiring additional pharmacodynamic and safety demonstration. Based on form, the dynamics between Injection, Syrup, and Tablet formats influence clinical use cases and supply chain choices; Injection demand is shaped by intramuscular and intravenous subsegments that impose distinct sterility and cold-chain requirements, Syrup offerings are influenced by sugar based and sugar free choices tied to patient populations and labeling expectations, while Tablet formats must balance extended release and immediate release profiles to meet analgesic regimens.

Based on application, differentiation between Cough Suppression and Pain Management carries implications for age segmentation and dosing strategies; cough suppression pathways further divide into adult formulations and pediatric formulations that require separate clinical and regulatory attention, and pain management splits into acute pain and chronic pain pathways that demand tailored benefit-risk assessments. Based on distribution channel, the roles of Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy affect inventory management, prescription validation, and patient counseling practices. Finally, based on end user, clinics, home care, and hospitals each present unique procurement behaviors and clinical governance frameworks that must be addressed through targeted commercial and clinical strategies to ensure appropriate access and oversight.

Regional comparative insights exposing regulatory variation, clinical access challenges, supply chain fragility, and demand trends guiding strategic priorities

Regional dynamics exert a persistent influence on how codeine products are regulated, supplied, and used in clinical practice, and variations by geography shape both short-term responses and long-term strategies. In the Americas, regulatory frameworks and healthcare delivery systems create a mix of centralized procurement and diverse prescribing practices, producing a landscape in which supplier reliability and distribution accountability are highly valued. In Europe, Middle East & Africa, fragmentation across regulatory regimes and heterogenous reimbursement environments combine with strong pharmacovigilance expectations to require regionally nuanced regulatory strategies and rigorous post-market monitoring. In Asia-Pacific, rapid expansion of healthcare infrastructure and varying degrees of local manufacturing capacity have produced both opportunities for domestic production and the need to harmonize quality standards to enable cross-border supply.

Across these regions, supply chain resilience, regulatory alignment, and clinical stewardship priorities diverge in emphasis but converge on shared objectives: preserving safe therapeutic access, ensuring traceable supply chains, and mitigating misuse. Strategic decisions regarding manufacturing footprint, regulatory submissions, and distribution partnerships must therefore be informed by region-specific constraints and enablers. Effective regional strategies incorporate local regulatory engagement, tailored clinical education initiatives, and commercially feasible logistics arrangements, enabling stakeholders to reconcile global product strategies with the operational realities of each geography.

Company insights into innovation strategies, portfolio diversification, manufacturing adaptability and partnerships shaping the competitive codeine landscape

Company-level dynamics in the codeine landscape reflect a balance between innovation, operational flexibility, and compliance with tightening regulatory requirements. Leading manufacturers and generic producers have prioritized portfolio diversification and formulation innovation to retain clinical relevance while addressing safety concerns and patient preferences. Strategic investments in sugar free syrup formulations, pediatric-appropriate dosing forms, and extended-release tablets demonstrate how product design can mitigate certain clinical risks and improve adherence across specific patient cohorts.

At the same time, manufacturing adaptability and supply chain transparency have emerged as core competitive differentiators. Companies that have invested in multi-sourced APIs, GMP-compliant facilities, and validated contract manufacturing partnerships are better positioned to navigate procurement disruptions and policy shifts. Commercial strategies increasingly emphasize collaborative relationships with healthcare systems, pharmacovigilance data sharing, and targeted clinical education to support appropriate use. Partnerships with contract research and manufacturing organizations enable faster scale-up and flexibility, while proprietary formulation know-how and robust quality systems sustain regulatory readiness and market access.

High-impact, pragmatic recommendations for industry leaders to balance patient access, regulatory compliance, supply security, and responsible opioid stewardship

To sustain therapeutic access while meeting heightened safety expectations and supply uncertainties, industry leaders should pursue a set of pragmatic, high-impact actions. Strengthening supplier networks and qualifying alternative API sources will reduce single-source risk and create room for agile manufacturing responses when trade policies or logistics issues arise. Concurrently, investing in formulation diversification-such as developing sugar free syrups, pediatric-friendly doses, and controlled-release tablets-aligns product offerings with evolving clinical guidance and patient needs. These investments should be coupled with enhanced pharmacovigilance systems and active collaboration with regulators to ensure labeling and usage guidance reflect best available evidence.

Commercially, organizations should prioritize transparent communication with healthcare providers and payers to build confidence in product quality and continuity. This includes targeted education programs on responsible prescribing, adverse-event reporting, and appropriate substitution where applicable. Operationally, leaders should consider capacity-building in contract manufacturing relationships and regional production hubs to buffer against external shocks. Finally, governance mechanisms that integrate compliance, clinical stewardship, and supply planning into executive decision-making will support balanced outcomes that preserve patient access while limiting misuse and diversion.

Methodology combining primary stakeholder interviews, regulatory review, clinical evidence synthesis, and multi-source validation to deliver actionable insights

The research underlying this analysis combines primary stakeholder engagement, regulatory review, clinical evidence synthesis, and rigorous multi-source validation to produce actionable findings. Primary inputs included structured interviews with clinicians, regulatory specialists, supply chain managers, and commercial leaders to capture operational realities and emergent practice patterns. Regulatory documents, clinical guidelines, and peer-reviewed literature were systematically reviewed to ground interpretation in current standards of care and safety expectations. Synthesis of these inputs enabled triangulation of clinical trends, formulation preferences, and distribution behaviors.

Data quality controls included cross-validation of interview findings against published guidance and manufacturing standards, and iterative expert feedback to refine interpretations and recommendations. Segmentation and regional analyses were constructed to align product, form, application, distribution, and end-user perspectives with geographic regulatory environments. The methodology prioritized transparency in assumptions and traceability of sources, enabling readers to follow the evidentiary basis for conclusions and to request tailored analyses aligned with specific commercial or operational questions.

Conclusion synthesizing clinical, regulatory, supply chain, and commercial imperatives that will shape near-term therapeutic use and stewardship priorities

In summary, the therapeutic and commercial trajectory for codeine products is shaped by intersecting forces: intensified regulatory scrutiny, evolving clinical alternatives, persistent supply chain vulnerabilities, and the need for prudent stewardship to minimize harm. These forces require integrated strategies that align product design, supply architecture, and clinician engagement to maintain safe access while reducing potential for misuse. As regulatory frameworks continue to evolve and trade dynamics exert influence on sourcing and pricing behavior, stakeholders who proactively adapt their manufacturing, procurement, and clinical support models will be best positioned to sustain reliable supply and clinical relevance.

Looking ahead, effective responses will combine investment in formulation and manufacturing flexibility with robust pharmacovigilance and targeted education for prescribers and patients. Embedding these approaches within corporate governance and regional operational plans will enable organizations to reconcile public health obligations with commercial viability. The imperative is clear: a coordinated, evidence-based approach that safeguards patient access while strengthening the resilience and accountability of the codeine supply chain will define success in the near term.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Codeine Market, by Product Type

  • 8.1. Codeine Hydrochloride
  • 8.2. Codeine Phosphate
  • 8.3. Codeine Sulfate
  • 8.4. Combination Products

9. Codeine Market, by Form

  • 9.1. Injection
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
  • 9.2. Syrup
    • 9.2.1. Sugar Based
    • 9.2.2. Sugar Free
  • 9.3. Tablet
    • 9.3.1. Extended Release
    • 9.3.2. Immediate Release

10. Codeine Market, by Application

  • 10.1. Cough Suppression
  • 10.2. Pain Management
    • 10.2.1. Acute Pain
    • 10.2.2. Chronic Pain

11. Codeine Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Codeine Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Codeine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Codeine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Codeine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Codeine Market

17. China Codeine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Accord Healthcare by Intas Pharmaceuticals
  • 18.7. Advik Pharma
  • 18.8. AstraEureka Pharmaceuticals
  • 18.9. Bristol Laboratories Limited
  • 18.10. Crescent Pharma Limited
  • 18.11. Johnson Matthey Plc
  • 18.12. Noramco, Inc.
  • 18.13. Omnica Laboratories
  • 18.14. Pfizer Inc.
  • 18.15. Professional Compounding Centers of America, Inc.
  • 18.16. SANOFI WINTHROP INDUSTRIE
  • 18.17. Sun Pharmaceutical Industries Ltd.
  • 18.18. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CODEINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CODEINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CODEINE MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CODEINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CODEINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CODEINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CODEINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CODEINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CODEINE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CODEINE MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CODEINE MARKET SIZE, BY SYRUP, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CODEINE MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CODEINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CODEINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)